{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:51:18Z","timestamp":1779317478258,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81702507"],"award-info":[{"award-number":["81702507"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Climbing Talent Project of Shanghai Tenth People\u2019s Hospital","award":["2018SYPDRC046"],"award-info":[{"award-number":["2018SYPDRC046"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Non-muscle invasive bladder cancer (NMIBC) represents the majority of bladder neoplasms. It is unusual for NMIBC metastasizing distantly without regional progression, namely metastatic NMIBC (mNMIBC), which is still poorly understood and easily omitted based on current management policies. So far, description of mNMIBC is limited to a few case reports.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We reported a 70-year-old man with NMIBC who suffered from cervical metastasis without pelvic recurrence at 41 months after initial diagnosis. Then we performed a collective analysis of this case together with published mNMIBC cases searched from PubMed, Embase, and Web of Science, aiming to illustrate baseline clinicopathologic parameters, metastatic patterns, and treatment outcomes of these patients and analyze associated influencing factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After scrupulous review, 45 cases previous reported and the one from our center were incorporated into the aggregated cohort of mNMIBC, including 34 males and 12 females. Primary tumors from 46.7% of patients were high-grade (HG) or grade 3 (G3) and 65.1% had T1 lesions. Aberrant biomarker expression was found in tumors of some cases. Most (40\/46) metastases of mNMIBC occurred at a single site, mainly in lung, bone and lymph nodes. Apart from three cases of de novo mNMIBC, the mean metastasis-free survival (MFS) interval of metachronous mNMIBC was 42.5 months, which was obviously longer than conventional metastatic bladder cancer. Shortened MFS interval was associated with old age, T1 or HG\/G3 primary tumors, and non-lung metastases. Systemic chemotherapy and metastasectomy or radiotherapy for oligometastatic lesion were main therapeutic approaches of mNMIBC, and immunotherapy was adopted for the case from our center. Lung and bone metastases correlated with relatively favorable and unfavorable survival outcomes, respectively. Compared with monotherapy, chemotherapy, or immunotherapy combined with local cytoreduction got more favorable outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Although rare, mNMIBC occurs more in tumors with high-risk features. Usually, mNMIBC metastasizes later than conventional metastatic bladder cancer and manifests as solitary lesion. Outcomes of mNMIBC would be influenced by metastatic site and post-metastatic treatment. Systemic treatment combined with local cytoreduction may render survival benefit in selected patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12957-022-02664-5","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T08:04:05Z","timestamp":1657094645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Distant metastasis without regional progression in non-muscle invasive bladder cancer: case report and pooled analysis of literature"],"prefix":"10.1186","volume":"20","author":[{"given":"Tianyuan","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyu","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianjin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leilei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xudong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"2664_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2664_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/1477-7819-12-301","volume":"12","author":"Y Bai","year":"2014","unstructured":"Bai Y, Liu L, Yuan H, Li J, Tang Y, Pu C, et al. Safety and efficacy of transurethral laser therapy for bladder cancer: a systematic review and meta-analysis. World J Surg Oncol. 2014;12:301.","journal-title":"World J Surg Oncol"},{"key":"2664_CR3","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12957-020-01943-3","volume":"18","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Zhang ZL, Luo MH, Yang H. Transurethral needle electrode resection and transurethral holmium laser resection of bladder cancer. World J Surg Oncol. 2020;18:166.","journal-title":"World J Surg Oncol"},{"key":"2664_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12957-018-1310-0","volume":"16","author":"P Zapala","year":"2018","unstructured":"Zapala P, Dybowski B, Poletajew S, Bialek L, Niewczas A, Radziszewski P. Clinical rationale and safety of restaging transurethral resection in indication-stratified patients with high-risk non-muscle-invasive bladder cancer. World J Surg Oncol. 2018;16:6.","journal-title":"World J Surg Oncol"},{"key":"2664_CR5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2147\/CMAR.S148856","volume":"9","author":"F Dong","year":"2017","unstructured":"Dong F, Shen Y, Gao F, Xu T, Wang X, Zhang X, et al. Prognostic value of site-specific metastases and therapeutic roles of surgery for patients with metastatic bladder cancer: a population-based study. Cancer Manag Res. 2017;9:611\u201326.","journal-title":"Cancer Manag Res"},{"key":"2664_CR6","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666\u201375.","journal-title":"J Clin Oncol"},{"key":"2664_CR7","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S0022-5347(17)49939-3","volume":"132","author":"PN Matthews","year":"1984","unstructured":"Matthews PN, Madden M, Bidgood KA, Fisher C. The clinicopathological features of metastatic superficial papillary bladder cancer. J Urol. 1984;132:904\u20136.","journal-title":"J Urol"},{"key":"2664_CR8","unstructured":"Sauter G, Algaba F, Amin MB, Busch C, Cheville J, Gasser T, Grignon D, Hofstaedter F, Lopez-Beltran A, Epstein JI. Non-invasive urothelial tumours. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. IARC Press; Lyon: 2004. 110."},{"key":"2664_CR9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.euo.2020.02.006","volume":"3","author":"AM Kamat","year":"2020","unstructured":"Kamat AM, Lerner SP, O'Donnell M, Georgieva MV, Yang M, Inman BA, et al. Evidence-based assessment of current and emerging bladder-sparing therapies for non-muscle-invasive bladder cancer after Bacillus Calmette-Guerin therapy: a systematic review and meta-analysis. Eur Urol Oncol. 2020;3:318\u201340.","journal-title":"Eur Urol Oncol"},{"key":"2664_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12957-018-1497-0","volume":"16","author":"PL Shen","year":"2018","unstructured":"Shen PL, Lin ME, Hong YK, He XJ. Bladder preservation approach versus radical cystectomy for high-grade non-muscle-invasive bladder cancer: a meta-analysis of cohort studies. World J Surg Oncol. 2018;16:197.","journal-title":"World J Surg Oncol"},{"key":"2664_CR11","doi-asserted-by":"publisher","first-page":"195.e7","DOI":"10.1016\/j.urolonc.2020.09.017","volume":"39","author":"R Hurle","year":"2021","unstructured":"Hurle R, Contieri R, Casale P, Morenghi E, Saita A, Buffi N, et al. Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure. Urol Oncol. 2021;39:195.e7\u2013195.e13.","journal-title":"Urol Oncol"},{"key":"2664_CR12","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1159\/000019636","volume":"33","author":"Y Fujii","year":"1998","unstructured":"Fujii Y, Fukui I, Kihara K, Tsujii T, Ishizaka K, Kageyama Y, et al. Significance of bladder neck involvement on progression in superficial bladder cancer. Eur Urol. 1998;33:464\u20138.","journal-title":"Eur Urol"},{"key":"2664_CR13","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/j.1464-410X.2011.10462.x","volume":"109","author":"R Segal","year":"2012","unstructured":"Segal R, Yafi FA, Brimo F, Tanguay S, Aprikian A, Kassouf W. Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy? BJU Int. 2012;109:1026\u201330.","journal-title":"BJU Int"},{"key":"2664_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1365-2184.2007.00424.x","volume":"40","author":"MM Nguyen","year":"2007","unstructured":"Nguyen MM, Lieu DK, deGraffenried LA, Isseroff RR, Kurzrock EA. Urothelial progenitor cells: regional differences in the rat bladder. Cell Prolif. 2007;40:157\u201365.","journal-title":"Cell Prolif"},{"key":"2664_CR15","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/S0022-5347(01)61608-2","volume":"161","author":"JH Mydlo","year":"1999","unstructured":"Mydlo JH, Weinstein R, Shah S, Solliday M, Macchia RJ. Long-term consequences from bladder perforation and\/or violation in the presence of transitional cell carcinoma: results of a small series and a review of the literature. J Urol. 1999;161:1128\u201332.","journal-title":"J Urol"},{"key":"2664_CR16","doi-asserted-by":"publisher","first-page":"bcr2014206631","DOI":"10.1136\/bcr-2014-206631","volume":"2014","author":"A Cusano","year":"2014","unstructured":"Cusano A, Murphy G, Haddock P, Wagner J. Tumour seeding as a result of intraperitoneal perforation during transurethral resection of non-muscle invasive bladder cancer. BMJ Case Rep. 2014;2014:bcr2014206631.","journal-title":"BMJ Case Rep"},{"key":"2664_CR17","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00345-013-1197-x","volume":"32","author":"E Comploj","year":"2014","unstructured":"Comploj E, Dechet CB, Mian M, Trenti E, Palermo S, Lodde M, et al. Perforation during TUR of bladder tumours influences the natural history of superficial bladder cancer. World J Urol. 2014;32:1219\u201323.","journal-title":"World J Urol"},{"key":"2664_CR18","doi-asserted-by":"publisher","first-page":"497.e17","DOI":"10.1016\/j.urolonc.2021.02.019","volume":"39","author":"R Nayyar","year":"2021","unstructured":"Nayyar R, Saini S, Sharma A, Kurra S, Dogra PN. Systemic dissemination of tumor cells during transurethral resection in patients with bladder tumor and its clinical relevance: a follow up study. Urol Oncol. 2021;39:497.e17\u201322.","journal-title":"Urol Oncol"},{"key":"2664_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12957-020-1808-0","volume":"18","author":"H Huang","year":"2020","unstructured":"Huang H, Wang T, Ahmed MG, Zhu L, Yang C, Li W, et al. Retrograde en bloc resection for non-muscle invasive bladder tumor can reduce the risk of seeding cancer cells into the peripheral circulation. World J Surg Oncol. 2020;18:33.","journal-title":"World J Surg Oncol"},{"key":"2664_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.critrevonc.2013.08.008","volume":"89","author":"L Cheng","year":"2014","unstructured":"Cheng L, Davison DD, Adams J, Lopez-Beltran A, Wang L, Montironi R, et al. Biomarkers in bladder cancer: translational and clinical implications. Crit Rev Oncol Hematol. 2014;89:73\u2013111.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2664_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","volume":"30","author":"J Hedegaard","year":"2016","unstructured":"Hedegaard J, Lamy P, Nordentoft I, Algaba F, Hoyer S, Ulhoi BP, et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell. 2016;30:27\u201342.","journal-title":"Cancer Cell"},{"key":"2664_CR22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/jjco\/hyaa219","volume":"51","author":"J Lu","year":"2021","unstructured":"Lu J, Zhang Y, Wu C, Chu C, Liu Z, Cao Y. Impact of immunohistochemistry-based molecular subtype on predicting chemotherapy response and survival in patients with T1 stage bladder cancer after bladder-preserving treatment. Jpn J Clin Oncol. 2021;51:424\u201333.","journal-title":"Jpn J Clin Oncol"},{"key":"2664_CR23","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.eururo.2016.12.016","volume":"71","author":"E Christensen","year":"2017","unstructured":"Christensen E, Birkenkamp-Demtroder K, Nordentoft I, Hoyer S, van der Keur K, van Kessel K, et al. Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer. Eur Urol. 2017;71:961\u20139.","journal-title":"Eur Urol"},{"key":"2664_CR24","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.juro.2010.04.016","volume":"184","author":"RT Bryan","year":"2010","unstructured":"Bryan RT, Tselepis C. Cadherin switching and bladder cancer. J Urol. 2010;184:423\u201331.","journal-title":"J Urol"},{"key":"2664_CR25","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1093\/jjco\/hyaa273","volume":"51","author":"G Rosiello","year":"2021","unstructured":"Rosiello G, Palumbo C, Deuker M, Stolzenbach LF, Martin T, Tian Z, et al. Sex- and age-related differences in the distribution of bladder cancer metastases. Jpn J Clin Oncol. 2021;51:976\u201383.","journal-title":"Jpn J Clin Oncol"},{"key":"2664_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2214\/AJR.10.5036","volume":"196","author":"AB Shinagare","year":"2011","unstructured":"Shinagare AB, Ramaiya NH, Jagannathan JP, Fennessy FM, Taplin ME, Van den Abbeele AD. Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor. AJR Am J Roentgenol. 2011;196:117\u201322.","journal-title":"AJR Am J Roentgenol"},{"key":"2664_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.euros.2021.07.006","volume":"32","author":"J Mason","year":"2021","unstructured":"Mason J, Hasnain Z, Miranda G, Gill K, Djaladat H, Desai M, et al. Prediction of metastatic patterns in bladder cancer: spatiotemporal progression and development of a novel, web-based platform for clinical utility. Eur Urol Open Sci. 2021;32:8\u201318.","journal-title":"Eur Urol Open Sci"},{"key":"2664_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.euf.2014.10.003","volume":"1","author":"LA Kluth","year":"2015","unstructured":"Kluth LA, Xylinas E, Rieken M, Kent M, Ikeda M, Matsumoto K, et al. Prognostic model for predicting survival in patients with disease recurrence following radical cystectomy. Eur Urol Focus. 2015;1:75\u201381.","journal-title":"Eur Urol Focus"},{"key":"2664_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/JU.0000000000000351","volume":"203","author":"DS Morera","year":"2020","unstructured":"Morera DS, Hasanali SL, Belew D, Ghosh S, Klaassen Z, Jordan AR, et al. Clinical parameters outperform molecular subtypes for predicting outcome in bladder cancer: results from multiple cohorts, including TCGA. J Urol. 2020;203:62\u201372.","journal-title":"J Urol"},{"key":"2664_CR30","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1007\/s00345-021-03721-6","volume":"39","author":"J Shou","year":"2021","unstructured":"Shou J, Zhang Q, Zhang D. The prognostic effect of metastasis patterns on overall survival in patients with distant metastatic bladder cancer: a SEER population-based analysis. World J Urol. 2021;39:4151\u20138.","journal-title":"World J Urol"},{"key":"2664_CR31","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1007\/s00345-019-03002-3","volume":"38","author":"R Hurle","year":"2020","unstructured":"Hurle R, Casale P, Saita A, Colombo P, Elefante GM, Lughezzani G, et al. Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based urine test, in active surveillance (AS) patients with recurrent non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance (BIAS) project. World J Urol. 2020;38:2215\u201320.","journal-title":"World J Urol"},{"key":"2664_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.832835","volume":"12","author":"V Fasulo","year":"2022","unstructured":"Fasulo V, Paciotti M, Lazzeri M, Contieri R, Casale P, Saita A, et al. Xpert bladder cancer monitor may avoid cystoscopies in patients under \"active surveillance\" for recurrent bladder cancer (BIAS Project): longitudinal cohort study. Front Oncol. 2022;12:832835.","journal-title":"Front Oncol"},{"key":"2664_CR33","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1097\/JU.0000000000001878","volume":"206","author":"R Zhang","year":"2021","unstructured":"Zhang R, Zang J, Xie F, Zhang Y, Wang Y, Jing Y, et al. Urinary molecular pathology for patients with newly diagnosed urothelial bladder cancer. J Urol. 2021;206:873\u201384.","journal-title":"J Urol"},{"key":"2664_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12957-018-1358-x","volume":"16","author":"F Dong","year":"2018","unstructured":"Dong F, Shen Y, Xu T, Wang X, Gao F, Zhong S, et al. Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis. World J Surg Oncol. 2018;16:61.","journal-title":"World J Surg Oncol"},{"key":"2664_CR35","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","volume":"36","author":"MY Teo","year":"2018","unstructured":"Teo MY, Seier K, Ostrovnaya I, Regazzi AM, Kania BE, Moran MM, et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers. J Clin Oncol. 2018;36:1685\u201394.","journal-title":"J Clin Oncol"},{"key":"2664_CR36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrurol.2017.172","volume":"15","author":"RC Walshaw","year":"2018","unstructured":"Walshaw RC, Honeychurch J, Illidge TM, Choudhury A. The anti-PD-1 era - an opportunity to enhance radiotherapy for patients with bladder cancer. Nat Rev Urol. 2018;15:251\u20139.","journal-title":"Nat Rev Urol"},{"key":"2664_CR37","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.eururo.2017.09.030","volume":"73","author":"M Abufaraj","year":"2018","unstructured":"Abufaraj M, Dalbagni G, Daneshmand S, Horenblas S, Kamat AM, Kanzaki R, et al. The role of surgery in metastatic bladder cancer: a systematic review. Eur Urol. 2018;73:543\u201357.","journal-title":"Eur Urol"},{"key":"2664_CR38","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1093\/annonc\/mdz296","volume":"30","author":"A Horwich","year":"2019","unstructured":"Horwich A, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committeesdagger. Ann Oncol. 2019;30:1697\u2013727.","journal-title":"Ann Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-022-02664-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-022-02664-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-022-02664-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T08:07:14Z","timestamp":1657094834000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-022-02664-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2664"],"URL":"https:\/\/doi.org\/10.1186\/s12957-022-02664-5","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]},"assertion":[{"value":"13 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a retrospectively collective study involving one human participant treated according to clinical practice at Shanghai Tenth People\u2019s Hospital. Permission granted by institutional ethical committee and informed consent from the patient were obtained. This article does not contain any studies with animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We have obtained informed consent from patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"226"}}